Merck and Moderna are developing a personalized mRNA vaccine intended to prevent melanoma from recurring or spreading after treatment.
The companies report positive first late-stage trial results for the vaccine combined with Keytruda, but have not released detailed data.
Pulse measures how actively a story is being covered right now.
Every article counts as a vote whose weight fades over time — an article published today counts as 1.0, one from two days ago counts 0.5, four days ago 0.25, and so on (a 2-day half-life). Pulse is the sum of those weights, so fresh coverage lifts it and old bursts fade away smoothly.